<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03695159</url>
  </required_header>
  <id_info>
    <org_study_id>STU 012018-005</org_study_id>
    <nct_id>NCT03695159</nct_id>
  </id_info>
  <brief_title>The Perioperative Management of Anti-thrombotic Drug Registry</brief_title>
  <acronym>CNCS</acronym>
  <official_title>The Perioperative Management of Anti-thrombotic Drug Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate contemporary antiplatelet therapy management of
      patients referred for non-cardiac and cardiac surgical procedures while on chronic therapy
      with antiplatelet and/or anticoagulant drugs. These medications are routinely prescribed to
      patients following percutaneous coronary interventions (PCI), known diagnosis of atrial
      fibrillation, prosthetic heart valves, transcatheter aortic valve procedures, pulmonary
      embolism, deep vein thrombosis, peripheral artery revascularization procedures etc. This is a
      highly relevant and understudied clinical area with no randomized clinical trials or
      large-scale prospective evidence, except for bridging data with unfractionated heparin (UFH).
      Most recommendations and guidelines are based on consensus expert opinion. While post-PCI
      patients, especially those treated with coronary stents are placed on dual antiplatelet
      agents such as aspirin and P2Y12 blocking agents, performing surgery while on these agents
      increase the risk of hemorrhagic complications, discontinuation or interruption of dual
      antiplatelet therapy (DAPT) has been associated with adverse ischemic outcomes secondary to
      myocardial infarction (MI) and stent thrombosis (ST). Moreover, there is only no clear
      consensus regarding continuation of aspirin perioperatively in these patients. As in the case
      of PCI, similar arguments for juxtaposed risks (thrombosis vs. bleeding) can be made for a
      myriad of clinical situations where chronic (≥45 days) use antiplatelet and anticoagulant
      medication (together referred to as antithrombotic drugs) are indicated. In addition, there
      are many procedures and surgeries with different bleeding and ischemic risks that cannot be
      studies through dedicated randomized studies and a registry collection of such information
      could provide valuable guidance to providers and patients worldwide.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2028</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>Clinical Outcomes (Net Adverse Cardiovascular events (%))</measure>
    <time_frame>time of study reporting initiation (14 days prior to CNCS) to end of study (30 days post-CNCS).</time_frame>
    <description>A composite of Death, Non-Fatal MI, Ischemic Stroke, Need for Urgent Coronary Revascularization, and Bleeding (defined by Bleeding Associated Research Consortium- BARC)</description>
  </primary_outcome>
  <enrollment type="Anticipated">12000</enrollment>
  <condition>Surgery</condition>
  <condition>Perioperative/Postoperative Complications</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients on chronic antiplatelet and anticoagulant therapies and undergo a cardiac and
        non-cardiac surgeries and procedures (CNCS)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment with antiplatelet and/or anticoagulant medications for ≥45 days prior to the
             date of NCS.

          -  Patients with planned, urgent or emergent cardiac or non-cardiac surgery or procedure
             (CNCS)

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Subhash Banerjee, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Subhash Banerjee, MD</last_name>
    <phone>2148571608</phone>
    <email>subhash.banerjee@UTSouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ishita Tejani, BDS,MS</last_name>
    <phone>2148573048</phone>
    <email>ishita.tejani@utsouthwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>North Texas VA Health Care System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amutha Baskar</last_name>
      <phone>214-857-0305</phone>
      <email>amutharani.baskar@va.gov</email>
    </contact>
    <investigator>
      <last_name>Nicole Minniefield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ishita Tejani, BDS, MS</last_name>
      <phone>214-857-3048</phone>
      <email>ishita.Tejani@UTSouthwestern.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P; European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013 May;15(5):625-51. doi: 10.1093/europace/eut083.</citation>
    <PMID>23625942</PMID>
  </reference>
  <reference>
    <citation>Beyer-Westendorf J, Gelbricht V, Förster K, Ebertz F, Köhler C, Werth S, Kuhlisch E, Stange T, Thieme C, Daschkow K, Weiss N. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J. 2014 Jul 21;35(28):1888-96. doi: 10.1093/eurheartj/eht557. Epub 2014 Jan 6.</citation>
    <PMID>24394381</PMID>
  </reference>
  <reference>
    <citation>Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, Garcia DA, Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AG, Hasselblad V, Ortel TL; BRIDGE Investigators. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med. 2015 Aug 27;373(9):823-33. doi: 10.1056/NEJMoa1501035. Epub 2015 Jun 22.</citation>
    <PMID>26095867</PMID>
  </reference>
  <reference>
    <citation>Tsimikas S. Drug-eluting stents and late adverse clinical outcomes lessons learned, lessons awaited. J Am Coll Cardiol. 2006 May 16;47(10):2112-5. Epub 2006 Apr 4.</citation>
    <PMID>16697332</PMID>
  </reference>
  <reference>
    <citation>Cruden NL, Harding SA, Flapan AD, Graham C, Wild SH, Slack R, Pell JP, Newby DE; Scottish Coronary Revascularisation Register Steering Committee. Previous coronary stent implantation and cardiac events in patients undergoing noncardiac surgery. Circ Cardiovasc Interv. 2010 Jun 1;3(3):236-42. doi: 10.1161/CIRCINTERVENTIONS.109.934703. Epub 2010 May 4.</citation>
    <PMID>20442357</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anti-thrombotic drugs</keyword>
  <keyword>cardiac intervention</keyword>
  <keyword>Non-cardiac intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

